Altimmune – Talk Bio

Recent Biotech News: Altimmune’s Pemvidutide Advances in MASH, Emerging China Obesity Players, and Ipsen Phase 2 Setback

3 weeks ago talkbio0Tagged Altimmune, China, Failed, IMPACT trial, Ipsen, MASH, Obesity, pemvidutide, Phase 2, United States Food and Drug Administration

Altimmune; pemvidutide; MASH; Phase 2b; IMPACT trial; FDA; China obesity; Ipsen; Phase 2 fail

FDA Considers Noninvasive Endpoint for MASH Trials, Boosts Biotech Shares

5 months ago talkbio0Tagged Altimmune, Biological Markers, Clinical Trials, Inventiva, Liver diseases, Madrigal Pharmaceuticals, MASH, Noninvasive Endpoint, stocks, United States Food and Drug Administration, Viking Therapeutics

FDA; noninvasive endpoint; liver disease; MASH; clinical trials; biomarker; biotech stocks; Madrigal Pharmaceuticals; Viking Therapeutics; Inventiva; Altimmune

Altimmune’s Incretin Misses Fibrosis Improvement Endpoints in MASH Trial

7 months ago talkbio0Tagged Altimmune, Clinical Trials, Fibrosis, Glucagon-Like Peptide 1, Incretins, MASH, pemvidutide

Altimmune; incretin; pemvidutide; fibrosis; MASH; GLP-1; clinical trial